CureVac and Rentschler Biopharma have initiated the set-up of manufacturing capabilities for CureVac´s COVID-19 vaccine, CVnCoV.
Rentschler Biopharma is gearing up for large-scale cGMP production of the formulated mRNA for CVnCoV. CureVac has started the clinical Phase 2b/3 trial with its mRNA-based vaccine candidate against SARS-CoV-2 and is preparing the start of commercial production to meet global demands. Rentschler Biopharma will contribute to the manufacturing of active pharmaceutical ingredient, downstream processing and formulation of drug substance for the vaccine.
The companies entered into a collaboration in November 2020 with the set-up of dedicated production lines at the Rentschler Biopharma site in Laupheim, Germany. Currently, optimisation of the production process is taking place to increase mRNA yield. The companies aim to produce more than 100 million doses of the CureVac vaccine per year in Laupheim.
Dr Florian von der Mülbe, Chief Production Officer of CureVac, said: "We are pleased to partner with Rentschler Biopharma, whose quality work is well known in the industry, to conduct key aspects of the CVnCoV production process. CureVac has started building an integrated European vaccine manufacturing network with several CDMO partners. With this strategy, the company will expect a significant increase in manufacturing capacity for CVnCoV, potentially reaching up to several hundred million doses per year while mitigating potential supply chain risks."
Dr Frank Mathias, CEO of Rentschler Biopharma, said: "Rentschler Biopharma has extensive experience in working with the most complex biopharmaceuticals and our expert team is dedicated to meeting CureVac's high expectations in producing their mRNA vaccine against COVID-19. We are preparing now to be ready to manufacture commercial supply, and are already setting up the production suite. We are currently looking to hire up to 80 highly qualified new team members, such as lab technicians and bioprocess engineers, to contribute to this important project and help us satisfy the increasing demand for life-saving biopharmaceuticals in the long-term."
